Jennifer Geremia,

MSPAS, PA-C

Jennifer Geremia,

MSPAS, PA-C
Physician Associate, Brigham and Women’s Hospital
and Teaching Hospital of Harvard Medical School

Jennifer Geremia,

MSPAS, PA-C
Physician Associate, Brigham and Women’s Hospital
and Teaching Hospital of Harvard Medical School
Jennifer Geremia, MSPAS, PA-C, is a practicing physician associate (PA) in outpatient gastroenterology (GI) and advanced endoscopy at Brigham and Women’s Hospital in Boston at Teaching Hospital of Harvard Medical School. With GI experience for 14 years, including providing community and tertiary care across the spectrum of GI disease states, Jennifer is committed to patient care. She obtained a master’s degree in physician assistant studies from Massachusetts College of Pharmacy and Health Sciences. She is part of the clinical faculty at Massachusetts College of Pharmacy and Health Sciences PA Program, adjunct professor with GI experience at the University of New England PA program, and the Massachusetts General Hospital School of Health Professions PA Program. Also, she is a conference faculty presenter for the Gastroenterology and Hepatology Advanced Practice Providers National Organization and an advanced practice provider contributor to the American Society for Gastrointestinal Endoscopy.

Jennifer's Shared Resources

Intermittent Fasting Is an Effective Way to Reverse Fatty Liver Disease

In an interview with the Fatty Liver Alliance, Dr. Jason Fung, a nephrologist, bestselling author, and co-founder of The Fasting...
Jennifer Geremia,
CURATED BY:
Jennifer Geremia,
MSPAS, PA-C

Bariatric Surgery Lowers Mortality and Heart Risk in MASLD Better Than Medications

A recent multicenter study of more than 8,600 patients with metabolic dysfunction-associated steatotic liver disease (MASLD) found that bariatric surgery...
Jennifer Geremia,
CURATED BY:
Jennifer Geremia,
MSPAS, PA-C

MASLD: Sharp Increases in Liver Disease Deaths by 2050

This decision analytical modeling study projected the long-term clinical burden of metabolic dysfunction-associated steatotic liver disease (MASLD) in the US...
Jennifer Geremia,
CURATED BY:
Jennifer Geremia,
MSPAS, PA-C

Sequential NIT Screening for MASH Reduces Biopsies and Costs

This study evaluated the diagnostic performance of non-invasive tests (NITs) like the FibroScan-AST (FAST) score, LSM-VCTE, FIB-4, and NFS for...
Jennifer Geremia,
CURATED BY:
Jennifer Geremia,
MSPAS, PA-C

Efruxifermin Shows Promise in Treating MASH, Targeting Liver Scarring

Efruxifermin, an experimental drug mimicking fibroblast growth factor 21 (FGF21), is being investigated in phase 3 SYNCHRONY trials for the...
Jennifer Geremia,
CURATED BY:
Jennifer Geremia,
MSPAS, PA-C

Challenges of Liver Transplantation for MASLD

Liver transplantation (LT) for metabolic dysfunction-associated steatotic liver disease (MASLD) is challenging due to high comorbidity rates, including obesity, diabetes,...
Jennifer Geremia,
CURATED BY:
Jennifer Geremia,
MSPAS, PA-C
Share